UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:PCMT1_LATS1 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: PCMT1_LATS1 | KinaseFusionDB ID: KFG4538 | FusionGDB2.0 ID: KFG4538 | Hgene | Tgene | Gene symbol | PCMT1 | LATS1 | Gene ID | 5110 | 9113 | |
Gene name | protein-L-isoaspartate (D-aspartate) O-methyltransferase | large tumor suppressor kinase 1 | ||||||||||
Synonyms | PIMT | WARTS|wts | ||||||||||
Cytomap | 6q25.1 | 6q25.1 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | protein-L-isoaspartate(D-aspartate) O-methyltransferaseL-isoaspartyl protein carboxyl methyltransferaseepididymis secretory sperm binding proteinprotein L-isoaspartyl/D-aspartyl methyltransferaseprotein-beta-aspartate methyltransferase | serine/threonine-protein kinase LATS1LATS (large tumor suppressor, Drosophila) homolog 1LATS, large tumor suppressor, homolog 1WARTS protein kinaseh-wartslarge tumor suppressor homolog 1 | ||||||||||
Modification date | 20240407 | 20240407 | ||||||||||
UniProtAcc | P22061 | O95835 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000367384, ENST00000367378, ENST00000464889, ENST00000367380, ENST00000544496, ENST00000480010, | ENST00000543571, ENST00000253339, ENST00000542747, ENST00000392273, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: PCMT1 [Title/Abstract] AND LATS1 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | PCMT1 | GO:0006479 | protein methylation | 3167043 |
Tgene | LATS1 | GO:0000086 | G2/M transition of mitotic cell cycle | 15122335 |
Tgene | LATS1 | GO:0000819 | sister chromatid segregation | 15122335 |
Tgene | LATS1 | GO:0006468 | protein phosphorylation | 10518011 |
Tgene | LATS1 | GO:0030833 | regulation of actin filament polymerization | 15220930 |
Tgene | LATS1 | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 20412773 |
Tgene | LATS1 | GO:0035329 | hippo signaling | 20412773 |
Tgene | LATS1 | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 9988268 |
Kinase Fusion gene breakpoints across PCMT1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across LATS1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
CCLE | NCI-H1838 | PCMT1 | chr6 | 150094305 | LATS1 | chr6 | 150016357 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
ENST00000367384 | ENST00000543571 | PCMT1 | chr6 | 150094305 | LATS1 | chr6 | 150016357 | 7272 | 1179 |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq >ENST00000367384_ENST00000543571_PCMT1_chr6_150094305_LATS1_chr6_150016357_length(amino acids)=1179 MQSPGSGSSHRGGRLGHTPPPPSAPPGRTLSRAASQSACVPRGMPGARSGGSGGDGSNSGSYSGDASGAVTVWEVVSLLGKLLGTVVALK VVLYLLRVCLAMAWKSGGASHSELIHNLRKNGIIKTDKVFEVMLATDRSHYAKCNPYMDSPQSIGFQATISAPHMDMVIQALQKTNNRSI EAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKGSKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGIS AFVQAHPSNGQRVNPPPPPQVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGYPPPPLNTSPMN PPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQNVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYT NGSIPQSMMVPNRNSHNMELYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQPSATTVTAITP APIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNVTVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSK EDQPSLPKEDESEKSYENVDSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHRKKQLENEMMRV GLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVCLARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEAD NEWVVRLYYSFQDKDNLYFVMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDGHIKLTDFGLCT GFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAARQHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILF EMLVGQPPFLAQTPLETQMKVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLRQQSASYIPKIT HPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTFRRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSE -------------------------------------------------------------- |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:/chr6:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
PCMT1 | LATS1 |
FUNCTION: Initiates the repair of damaged proteins by catalyzing methyl esterification of L-isoaspartyl and D-aspartyl residues produced by spontaneous isomerization and racemization of L-aspartyl and L-asparaginyl residues in aging peptides and proteins (PubMed:3167043, PubMed:6469980). Acts on EIF4EBP2, microtubule-associated protein 2, calreticulin, clathrin light chains a and b, Ubiquitin C-terminal hydrolase isozyme L1, phosphatidylethanolamine-binding protein 1, stathmin, beta-synuclein and alpha-synuclein (By similarity). {ECO:0000250|UniProtKB:P23506, ECO:0000269|PubMed:3167043, ECO:0000269|PubMed:6469980}. | FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function. Plays a role in mammary gland epithelial cell differentiation, both through the Hippo signaling pathway and the intracellular estrogen receptor signaling pathway by promoting the degradation of ESR1 (PubMed:28068668). {ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:10831611, ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:28068668}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Tgene | PCMT1 | 150094305 | LATS1 | 150016357 | ENST00000367384 | 0 | 7 | 1011_1090 | 116 | 1131 | Domain | Note=AGC-kinase C-terminal;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00618 |
Tgene | PCMT1 | 150094305 | LATS1 | 150016357 | ENST00000367384 | 1 | 4 | 1011_1090 | 116 | 691 | Domain | Note=AGC-kinase C-terminal;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00618 |
Tgene | PCMT1 | 150094305 | LATS1 | 150016357 | ENST00000367384 | 1 | 8 | 1011_1090 | 116 | 1131 | Domain | Note=AGC-kinase C-terminal;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00618 |
Tgene | PCMT1 | 150094305 | LATS1 | 150016357 | ENST00000367384 | 0 | 7 | 705_1010 | 116 | 1131 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
Tgene | PCMT1 | 150094305 | LATS1 | 150016357 | ENST00000367384 | 1 | 4 | 705_1010 | 116 | 691 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
Tgene | PCMT1 | 150094305 | LATS1 | 150016357 | ENST00000367384 | 1 | 8 | 705_1010 | 116 | 1131 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
Top |
Kinase Fusion Protein Structures |
CIF files of the predicted kinase fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB) | Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | AA seq | Len(AA seq) |
PDB file >>>368_PCMT1_LATS1 | ENST00000367384 | ENST00000543571 | PCMT1 | chr6 | 150094305 | LATS1 | chr6 | 150016357 | MQSPGSGSSHRGGRLGHTPPPPSAPPGRTLSRAASQSACVPRGMPGARSGGSGGDGSNSGSYSGDASGAVTVWEVVSLLGKLLGTVVALK VVLYLLRVCLAMAWKSGGASHSELIHNLRKNGIIKTDKVFEVMLATDRSHYAKCNPYMDSPQSIGFQATISAPHMDMVIQALQKTNNRSI EAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKGSKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGIS AFVQAHPSNGQRVNPPPPPQVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGYPPPPLNTSPMN PPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQNVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYT NGSIPQSMMVPNRNSHNMELYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQPSATTVTAITP APIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNVTVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSK EDQPSLPKEDESEKSYENVDSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHRKKQLENEMMRV GLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVCLARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEAD NEWVVRLYYSFQDKDNLYFVMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDGHIKLTDFGLCT GFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAARQHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILF EMLVGQPPFLAQTPLETQMKVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLRQQSASYIPKIT HPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTFRRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSE | 1179 |
3D view using mol* of 368_PCMT1_LATS1 | ||||||||||
PDB file >>>TKFP_638_PCMT1_LATS1 | ENST00000367384 | ENST00000543571 | PCMT1 | chr6 | 150094305 | LATS1 | chr6 | 150016357 | MQSPGSGSSHRGGRLGHTPPPPSAPPGRTLSRAASQSACVPRGMPGARSGGSGGDGSNSGSYSGDASGAVTVWEVVSLLGKLLGTVVALK VVLYLLRVCLAMAWKSGGASHSELIHNLRKNGIIKTDKVFEVMLATDRSHYAKCNPYMDSPQSIGFQATISAPHMDMVIQALQKTNNRSI EAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKGSKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGIS AFVQAHPSNGQRVNPPPPPQVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGYPPPPLNTSPMN PPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQNVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYT NGSIPQSMMVPNRNSHNMELYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQPSATTVTAITP APIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNVTVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSK EDQPSLPKEDESEKSYENVDSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHRKKQLENEMMRV GLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVCLARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEAD NEWVVRLYYSFQDKDNLYFVMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDGHIKLTDFGLCT GFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAARQHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILF EMLVGQPPFLAQTPLETQMKVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLRQQSASYIPKIT HPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTFRRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSE | 1179_PCMT1_LATS1 |
Top |
Comparison of Fusion Protein Isoforms |
Superimpose the 3D Structures Among All Fusion Protein Isoforms * Download the pdb file and open it from the molstar online viewer. |
Comparison of the Secondary Structures of Fusion Protein Isoforms |
Top |
Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB |
Top |
pLDDT score distribution |
pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. * The blue color at the bottom marks the best active site residues. |
368_PCMT1_LATS1.png |
368_PCMT1_LATS1.png |
Top |
Potential Active Site Information |
The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
Kinase Fusion AA seq ID in KinaseFusionDB | Site score | Size | Dscore | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
Top |
Ramachandran Plot of Kinase Fusion Protein Structure |
Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
368_PCMT1_LATS1_ramachandran.png |
Top |
Virtual Screening Results |
Distribution of the average docking score across all approved kinase inhibitors. Distribution of the number of occurrence across all approved kinase inhibitors. |
5'-kinase fusion protein case |
3'-kinase fusion protein case |
Top |
Drug information from DrugBank of the top 20 interacting small molecules. * The detailed information of individual kinase inhibitors are available in the download page. |
Fusion gene name info | Drug | Docking score | Glide g score | Glide energy |
Top |
Kinase-Substrate Information of PCMT1_LATS1 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
LATS1 | O95835 | human | INCENP | Q9NQS7 | S894 | RYHKRtssAVWNsPP | |
LATS1 | O95835 | human | YAP1 | P46937 | S397 | tyHSRDEstDsGLsM | |
LATS1 | O95835 | human | YAP1 | P46937 | S61 | IVHVRGDsEtDLEAL | |
LATS1 | O95835 | human | MAP3K11 | Q16584 | T477 | HVRRRRGtFKRSKLR | |
LATS1 | O95835 | human | SASH1 | O94885 | S407 | LSHGRtCsFGGFDLT | SLY |
LATS1 | O95835 | human | CDC26 | Q8NHZ8 | T7 | _MLRRKPtRLELKLD | ANAPC_CDC26 |
LATS1 | O95835 | human | RPTOR | Q8N122 | S606 | SAHEkLYsLLSDPIP | HEAT |
LATS1 | O95835 | human | SNAI2 | O43623 | T208 | QGHIRtHtGEkPFSC | |
LATS1 | O95835 | human | LATS1 | O95835 | S674 | EMMRVGLsQDAQDQM | |
LATS1 | O95835 | human | LATS1 | O95835 | S909 | HQRCLAHsLVGTPNY | Pkinase |
LATS1 | O95835 | human | YAP1 | P46937 | S381 | LRTMTTNssDPFLNs | |
LATS1 | O95835 | human | YAP1 | P46937-2 | S61 | IVHVRGDsEtDLEAL | |
LATS1 | O95835 | human | MTF1 | Q14872 | S152 | EGCPRTysTAGNLRT | zf-C2H2 |
LATS1 | O95835 | human | PRPS1 | P60891 | S285 | EDkMKHCsKIQVIDI | Pribosyl_synth |
LATS1 | O95835 | human | RAF1 | P04049 | S259 | sQRQRststPNVHMV | |
LATS1 | O95835 | human | KIF23 | Q02241 | S814 | LRHRRsRsAGDRWVD | MKLP1_Arf_bdg |
LATS1 | O95835 | human | AMOT | Q4VCS5 | S175 | QGHVRSLsERLMQMS | |
LATS1 | O95835 | human | YAP1 | P46937-2 | S109 | KsHsRQAstDAGtAG | |
LATS1 | O95835 | human | KIF23 | Q02241 | S716 | QLHRRsNsCsSISVA | |
LATS1 | O95835 | human | YAP1 | P46937 | S127 | PQHVRAHssPAsLQL | |
LATS1 | O95835 | human | LATS1 | O95835 | S1049 | VDPDkLWsDDNEEEN | |
LATS1 | O95835 | human | PRPS2 | P11908 | T285 | EDkMkHCtKIQVIDI | Pribosyl_synth |
LATS1 | O95835 | human | YAP1 | P46937-2 | S127 | PQHVRAHssPASLQL | |
LATS1 | O95835 | human | YAP1 | P46937 | S109 | ksHsRQAstDAGtAG | |
LATS1 | O95835 | human | YAP1 | P46937-2 | S164 | AQHLRQssFEIPDDV | |
LATS1 | O95835 | human | YAP1 | P46937-2 | S381 | TYHSRDEsTDsGLsM | |
LATS1 | O95835 | human | WWTR1 | Q9GZV5 | S89 | AQHVRsHssPAsLQL |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
LATS1 | ID | Description | 0.00e+00 |
LATS1 | GO:0035329 | hippo signaling | 2.51e-05 |
LATS1 | GO:0051256 | mitotic spindle midzone assembly | 4.29e-03 |
LATS1 | GO:0000022 | mitotic spindle elongation | 4.29e-03 |
LATS1 | GO:0072182 | regulation of nephron tubule epithelial cell differentiation | 4.29e-03 |
LATS1 | GO:0060828 | regulation of canonical Wnt signaling pathway | 4.29e-03 |
LATS1 | GO:0051231 | spindle elongation | 4.29e-03 |
LATS1 | GO:0051255 | spindle midzone assembly | 4.29e-03 |
LATS1 | GO:0072160 | nephron tubule epithelial cell differentiation | 4.29e-03 |
LATS1 | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 4.29e-03 |
LATS1 | GO:0071900 | regulation of protein serine/threonine kinase activity | 4.29e-03 |
LATS1 | GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 4.29e-03 |
LATS1 | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 4.29e-03 |
LATS1 | GO:0060070 | canonical Wnt signaling pathway | 5.11e-03 |
LATS1 | GO:0006098 | pentose-phosphate shunt | 5.52e-03 |
LATS1 | GO:0030111 | regulation of Wnt signaling pathway | 5.52e-03 |
LATS1 | GO:0072234 | metanephric nephron tubule development | 5.52e-03 |
LATS1 | GO:0006740 | NADPH regeneration | 5.52e-03 |
LATS1 | GO:0072202 | cell differentiation involved in metanephros development | 5.52e-03 |
LATS1 | GO:0033135 | regulation of peptidyl-serine phosphorylation | 5.52e-03 |
LATS1 | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 5.52e-03 |
LATS1 | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 5.52e-03 |
LATS1 | GO:0072170 | metanephric tubule development | 5.52e-03 |
LATS1 | GO:0072243 | metanephric nephron epithelium development | 5.52e-03 |
LATS1 | GO:1900180 | regulation of protein localization to nucleus | 5.52e-03 |
LATS1 | GO:0045598 | regulation of fat cell differentiation | 5.63e-03 |
LATS1 | GO:0045667 | regulation of osteoblast differentiation | 5.86e-03 |
LATS1 | GO:0051156 | glucose 6-phosphate metabolic process | 6.13e-03 |
LATS1 | GO:0072207 | metanephric epithelium development | 6.13e-03 |
LATS1 | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 6.13e-03 |
LATS1 | GO:0043507 | positive regulation of JUN kinase activity | 6.59e-03 |
LATS1 | GO:0030856 | regulation of epithelial cell differentiation | 7.23e-03 |
LATS1 | GO:0030178 | negative regulation of Wnt signaling pathway | 7.25e-03 |
LATS1 | GO:0009156 | ribonucleoside monophosphate biosynthetic process | 7.42e-03 |
LATS1 | GO:0033146 | regulation of intracellular estrogen receptor signaling pathway | 7.42e-03 |
LATS1 | GO:0016055 | Wnt signaling pathway | 7.86e-03 |
LATS1 | GO:0198738 | cell-cell signaling by wnt | 7.86e-03 |
LATS1 | GO:0050673 | epithelial cell proliferation | 8.91e-03 |
LATS1 | GO:0009124 | nucleoside monophosphate biosynthetic process | 9.99e-03 |
LATS1 | GO:0006739 | NADP metabolic process | 9.99e-03 |
LATS1 | GO:0043506 | regulation of JUN kinase activity | 9.99e-03 |
LATS1 | GO:0001825 | blastocyst formation | 1.02e-02 |
LATS1 | GO:0010837 | regulation of keratinocyte proliferation | 1.04e-02 |
LATS1 | GO:0032467 | positive regulation of cytokinesis | 1.04e-02 |
LATS1 | GO:0035850 | epithelial cell differentiation involved in kidney development | 1.04e-02 |
LATS1 | GO:0000819 | sister chromatid segregation | 1.11e-02 |
LATS1 | GO:0097191 | extrinsic apoptotic signaling pathway | 1.14e-02 |
LATS1 | GO:0030520 | intracellular estrogen receptor signaling pathway | 1.28e-02 |
LATS1 | GO:2001234 | negative regulation of apoptotic signaling pathway | 1.30e-02 |
LATS1 | GO:0045444 | fat cell differentiation | 1.34e-02 |
Top |
Related Drugs to PCMT1_LATS1 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning PCMT1-LATS1 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to PCMT1_LATS1 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |